Vascular Diseases of the Liver
Susana Seijo
Hospital Clínic-Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Search for more papers by this authorLaurie D. DeLeve
Keck School of Medicine of USC, Los Angeles, CA, USA
Search for more papers by this authorSusana Seijo
Hospital Clínic-Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Search for more papers by this authorLaurie D. DeLeve
Keck School of Medicine of USC, Los Angeles, CA, USA
Search for more papers by this authorDaniel K. Podolsky MD
President, University of Texas Southwestern Medical Center, Professor of Internal Medicine, Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, TX, USA
Search for more papers by this authorMichael Camilleri MD
Executive Dean for Development, Atherton and Winifred W. Bean Professor, Professor of Medicine, Physiology and Pharmacology, Distinguished Investigator, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorJ. Gregory Fitz MD FAASLD
Executive Vice President for Academic Aff airs and Provost, University of Texas Southwestern Medical Center, Dean, Professor of Internal Medicine, Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, TX, USA
Search for more papers by this authorAnthony N. Kalloo MD
Professor of Medicine, Johns Hopkins University School of Medicine, Director, Division of Gastroenterology & Hepatology, Johns Hopkins Hospital, Baltimore, MD, USA
Search for more papers by this authorFergus Shanahan MD
Professor and Chair, Department of Medicine, Director, Alimentary Pharmabiotic Centre, University College Cork, National University of Ireland, Cork, Ireland
Search for more papers by this authorTimothy C. Wang MD
Chief, Division of Digestive and Liver Diseases, Silberberg Professor of Medicine, Department of Medicine and Irving Cancer Research Center, Columbia University Medical Center, New York, NY, USA
Search for more papers by this authorSummary
This chapter provides an overview of vascular diseases of the liver. Several rare diseases are included within this term, the most important being Budd-Chiari syndrome (BCS), portal vein thrombosis (PVT), sinusoidal obstruction syndrome (SOS) and adaptation to heterogenous perfusion. BCS and PVT are mainly caused by prothrombotic diseases and they frequently develop non-cirrhotic portal hypertension-related complications. SOS is caused most often by drugs and chemotherapy regimens and its clinical presentation ranges from asymptomatic to severe hepatic and multiorgan failure. The term adaptation to heterogenous perfusion includes a variety of rare entities such as nodular regenerative hyperplasia, hepatoportal sclerosis, non-cirrhotic portal cirrhosis, and obliterative portal venopathy, suggesting that they could constitute a single entity with a common pathogenic mechanism that results in a spectrum of pathological lesions and clinical manifestations. This chapter also considers ischemic hepatitis, congestive hepatopathy and peliosis hepatis.
References
- Condat B., Pessione F., Hillaire S., et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001; 120: 490.
- Darwish Murad S., Plessier A., Hernandez-Guerra M., et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009; 151: 167.
- Darwish Murad S., Valla D.C., de Groen P.C., et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39: 500.
- DeLeve L.D., Shulman H.M., McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venoocclusive disease). Semin Liver Dis 2002; 22: 623.
- DeLeve L.D., Valla D.C., Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009; 49: 1729.
- Hogan W.J., Maris M., Storer B., et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004; 103: 78.
- Plessier A., Darwish-Murad S., Hernandez-Guerra M., et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 2010; 51: 210.
- Schouten J.N., Garcia-Pagan J.C., Valla D.C., et al. Idiopathic noncirrhotic portal hypertension. Hepatology 2011; 54: 1071.
- Turnes J., Garcia-Pagan J.C., Gonzalez M., et al. Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol 2008; 6: 1412.
- Gibson PR, Dudley FJ. Ischemic hepatitis: clinical features, diagnosis and prognosis. Aust N Z J Med 1984; 14: 822.
- Henrion J, Minette P, Colin L, et al. Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: a case-controlled, hemodynamic study of 17 consecutive cases. Hepatology 1999; 29: 427.
- Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 2000; 109: 109.
- Gitlin N, Serio KM. Ischemic hepatitis: widening horizon. Am J Gastroenterol 1992; 87: 831.
- Cassidy WM, Reynolds TB. Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J Clin Gastroenterol 1994; 19: 118.
- Henrion J, Schapira M, Heller FR. Ischemic hepatitis: the need for precise criteria (letter). J Clin Gastroenterol 1996; 23: 305.
- Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clin Liver Dis 2002; 6: 947.
- Henrion J, Schapira M, Luwaert R, et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine 2003; 82: 392.
- de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762.
- Janssen HL, Garcia-Pagan JC, Elias E, et al. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003; 38: 364.
- DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009; 49: 1729.
- Kage M, Arakawa M, Kojiro M, et al. Histopathology of membranous obstruction of the inferior vena cava in the Budd-Chiari syndrome. Gastroenterology 1992; 102: 2081.
- Shrestha SM, Joshi BL, Shrestha S, et al. Cavographic study of inferior vena cava obstruction. Cavographic study of an early stage of obstruction of the hepatic portion of the inferior vena cava. J Gastroenterol Hepatol 2000; 15: 202.
- Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31: 587.
- Janssen HL, Meinardi JR, Vleggaar FP, et al. Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000; 96: 2364.
- Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009; 151: 167.
- Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985; 103: 329.
- Valla D, Casadevall N, Huisse MG, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988; 94: 1063.
- De Stefano V, Teofili L, Leone G, et al. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997; 23: 411.
- Primignani M, Mannucci PM. The role of thrombophilia in splanchnic vein thrombosis. Semin Liver Dis 2008; 28: 293.
- Bismuth E, Hadengue A, Hammel P, et al. Hepatic vein thrombosis in Behcet's disease. Hepatology 1990; 11: 969.
- Saatci I, Ozmen M, Balkanci F, et al. Behcet's disease in the etiology of Budd-Chiari disease. Angiology 1993; 44: 392.
- de Bruijne EL, Darwish Murad S, de Maat MP, et al. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thromb Haemost 2007; 97: 181.
- Hoekstra J, Guimaraes AH, Leebeek FW, et al. Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood 2010; 115: 388.
- Talens S, Hoekstra J, Dirkx SP, et al. Proteomic analysis reveals that apolipoprotein A1 levels are decreased in patients with Budd-Chiari syndrome. J Hepatol 2011; 54: 908.
- Young RC. The Budd-Chiari syndrome caused by Aspergillus; two patients with vascular invasion of the hepatic veins. Arch Intern Med 1969; 124: 754.
- Darwish Murad S, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39: 500.
- Okuda H, Yamagata H, Obata H, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol 1995; 22: 1.
- Dilawari JB, Bambery P, Chawla Y, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994; 73: 21.
- Cazals-Hatem D, Vilgrain V, Genin P, et al. Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers. Hepatology 2003; 37: 510.
- Darwish Murad S, Valla DC, de Groen PC, et al. Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis. Am J Gastroenterol 2006; 101: 83.
- Mahmoud AEA, Helmy AS, Billingham S, et al. Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndroem and portal venous system thrombosis. Eur J Gastroenterol Hepatol 1997; 9: 485.
- Tanaka M, Wanless IR. Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of veno-centric cirrhosis, veno-portal cirrhosis, and large regenerative nodules. Hepatology 1998; 27: 488.
- Hadengue A, Poliquin M, Vilgrain V, et al. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology 1994; 106: 1042.
- Miller WJ, Federle MP, Straub WH, et al. Budd-Chiari syndrome: imaging with pathologic correlation. Abdom Imaging 1993; 18: 329.
- Flor N, Zuin M, Brovelli F, et al. Regenerative nodules in patients with chronic Budd-Chiari syndrome: a longitudinal study using multiphase contrast-enhanced multidetector CT. Eur J Radiol 2010; 73: 588.
- Moucari R, Rautou PE, Cazals-Hatem D, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut 2008; 57: 828.
- Park H, Yoon JY, Park KH, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: a single center experience with long-term follow-up in South Korea. World J Gastroenterol 2012; 18: 1946.
- Hernandez-Guerra M, Lopez E, Bellot P, et al. Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. Hepatology 2006; 43: 27.
- Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005; 129: 553.
- Dayal S, Pati HP, Pande GK, et al. Multilineage hemopoietic stem cell defects in Budd Chiari syndrome. J Hepatol 1997; 26: 293.
- Hirshberg B, Shouval D, Fibach E, et al. Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome. J Hepatol 2000; 32: 574.
- Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528.
- Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008; 111: 4922.journal>
- Smalberg JH, Murad SD, Braakman E, et al. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 2006; 91: 1712.
- Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130: 2031.
- Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092.
- Bittencourt PL, Couto CA, Ribeiro DD. Portal vein thrombosis and Budd-Chiari syndrome. Clin Liver Dis 2009; 13: 127.
- Tefferi A, Solberg LA, Silverstein MN. A clinical update in polycythemia vera and essential thrombocythemia. Am J Med 2000; 109: 141.
- Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997; 34: 17.
- Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132.
- Rautou PE, Angermayr B, Garcia-Pagan JC, et al. Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes. J Hepatol 2009; 51: 47.
- Sharma S, Texeira A, Texeira P, et al. Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol 2004; 40: 172.
- Zhang CQ, Fu LN, Xu L, et al. Long-term effect of stent placement in 115 patients with Budd-Chiari syndrome. World J Gastroenterol 2003; 9: 2587.
-
DeLeve LD,
Kanel GC.
Vascular diseases of the liver. In:
T Yamada,
DH Alpers,
N Kaplowitz, et al. (eds).
Atlas of Gastroenterology,
4th ed.
Oxford:
Blackwell Publishing;
2009:
731.
10.1002/9781444303414.ch70 Google Scholar
- Hernandez-Guerra M, Turnes J, Rubinstein P, et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology 2004; 40: 1197.
- Perello A, Garcia-Pagan JC, Gilabert R, et al. TIPS is a useful long-term derivative therapy for patients with Budd- Chiari syndrome uncontrolled by medical therapy. Hepatology 2002; 35: 132.
- Bachet JB, Condat B, Hagege H, et al. Long-term portosystemic shunt patency as a determinant of outcome in Budd-Chiari syndrome. J Hepatol 2007; 46: 60.
- Mentha G, Giostra E, Majno PE, et al. Liver transplantation for Budd-Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol 2006; 44: 520.
- Segev DL, Nguyen GC, Locke JE, et al. Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis. Liver Transpl 2007; 13: 1285.
- Garcia-Pagan JC, Hernandez-Guerra M, Bosch J. Extrahepatic portal vein thrombosis. Semin Liver Dis 2008; 28: 282.
- Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 2010; 51: 210.
- Valla D, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis, and management. J Hepatol 2000; 32: 865.
- Rosenberg RD, Aird WC. Vascular-bed–specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340: 1555.
- Turnes J, Garcia-Pagan JC, Gonzalez M, et al. Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol 2008; 6: 1412.
- Bach AM, Hann LE, Brown KT, et al. Portal vein evaluation with US: comparison to angiography combined with CT arterial portography. Radiology 1996; 201: 149.
- Mathieu D, Vasile N, Grenier P. Portal thrombosis. Dynamic CT features and course. Radiology 1985; 154: 737.
- Condat B, Pessione F, Helene Denninger M, et al. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32: 466.
- Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med 2001; 345: 1683.
- Gupta D, Vijaya DR, Gupta R, et al. Prevalence of hepatopulmonary syndrome in cirrhosis and extrahepatic portal venous obstruction. Am J Gastroenterol 2001; 96: 3395.
- Llop E, de Juan C, Seijo S, et al. Portal cholangiopathy: radiological classification and natural history. Gut 2011; 60: 853.
- Fanelli F, Angeloni S, Salvatori FM, et al. Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma. Dig Liver Dis 2011; 43: 78.
- Qi X, Han G, Yin Z, et al. Transjugular intrahepatic portosystemic shunt for portal cavernoma with symptomatic portal hypertension in non-cirrhotic patients. Dig Dis Sci 2012; 57: 1072.
- Condat B, Pessione F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001; 120: 490.
- Kitchens CS, Weidner MH, Lottenberg R. Chronic oral anticoagulant therapy for extrahepatic visceral thrombosis is safe. J Thromb Thrombolysis 2007.
- Orr DW, Harrisson PM, Karani J, et al. Chronic portomesenteric and portosplenomesenteric venous thrombosis: evaluation of long term follow-up and determinants of survival. Hepatology 2005; 42: 212A.
- Dumortier J, Vaillant E, Boillot O, et al. Diagnosis and treatment of biliary obstruction caused by portal cavernoma. Endoscopy 2003; 35: 446.
- Luca A, Miraglia R, Caruso S, et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut 2011; 60: 846.
- Senzolo M, Tibbals J, Cholongitas E, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther 2006; 23: 767.
- Bras G, Jeliffe DB, Stuart KL. Veno-occlusive disease of the liver with non-portal type of cirrhosis occurring in Jamaica. Arch Pathol 1954; 57: 285.
- Shulman HM, Fisher LB, Schoch HG, et al. Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994; 19: 1171.
- Rollins BJ. Hepatic veno-occlusive disease. Am J Med 1986; 81: 297.
- DeLeve LD, McCuskey RS, Wang X, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999; 29: 1779.
- DeLeve LD, Ito Y, Machen NW, et al. Embolization by sinusoidal lining cells causes the congestion of hepatic venoocclusive disease. Gastroenterology 2000; 118: A2345.
- DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venoocclusive disease). Semin Liver Dis 2002; 22: 623.
- DeLeve LD. Dacarbazine toxicity in murine liver cells: a novel model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther 1994; 268: 1261.
- DeLeve LD, Wang X, Kuhlenkamp JF, et al. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venooclusive disease. Hepatology 1996; 23: 589.
- DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996; 24: 830.
- DeLeve LD, Wang X, Tsai J, et al. Prevention of sinusoidal obstruction syndrome (hepatic venoocclusive disease) in the rat by matrix metalloproteinase inhibitors. Gastroenterology 2003; 125: 882.
- DeLeve LD, Wang X, Kanel GC, et al. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology 2003; 38: 900.
- Shulman HM, McDonald GB, Matthews D, et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980; 79: 1178.
- McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation – a cohort study of 355 patients. Ann Intern Med 1993; 118: 255.
- Jones RJ, Lee KSK, Beschorner WE, et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778.
- Haboubi NY, Ali HH, Whitwell HL, et al. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am J Gastroenterol 1988; 83: 256.
- Sterneck M, Wiesner R, Ascher N, et al. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991; 14: 806.
- Gane E, Portmann B, Saxena R, et al. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994; 20: 88.
- Katzka DA, Saul SH, Jorkasky D, et al. Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology 1986; 90: 446.
- Eisenhauer T, Hartmann H, Rumpf KW, et al. Favourable outcome of hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine, treated by portacaval shunt. Report of a case and review of the literature. Digestion 1984; 30: 185.
- Kao NL, Rosenblate HJ. 6-thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease. J Am Acad Dermatol 1993; 28: 1017.
- DeLeve LD. Liver function and hepatotoxicity in cancer. Chapter 151. In: JF Holland, E Frei, RC Bast, et al. (eds). Cancer Medicine, 5th ed. Hamilton, Ontario, Canada: B.C. Decker Inc; 2000.
-
Giles FJ,
Kantarjian HM,
Kornblau SM, et al.
Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Cancer
2001;
92:
406.
10.1002/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U CAS PubMed Web of Science® Google Scholar
- Tack DK, Letendre L, Kamath PS, et al. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant 2001; 28: 895.
- Rajvanshi P, Shulman HM, Sievers EL, et al. Hepatic sinusoidal obstruction following Gemtuzumab Ozogamicin (Mylotarg®). Blood 2002; 99: 2310.
- Neumeister P, Eibl M, Zinke-Cerwenka W, et al. Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate. Ann Hematol 2001; 80: 119.
- Czauderna P, Katski K, Kowalczyk J, et al. Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients. Eur J Pediatr Surg 2000; 10: 300.
- Tornesello A, Piciacchia D, Mastrangelo S, et al. Veno-occlusive disease of the liver in right-sided Wilms' tumours. Eur J Cancer 1998; 34: 1220.
- Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578.
- Lee JL, Gooley T, Bensinger W, et al. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999; 5: 306.
- McDonald GB. Liver disease of uncertain cause. Bone Marrow Transplant 2004; 33: 977.
- Shulman HM, Gooley T, Dudley MD, et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995; 59: 1015.
- Cordonnier C, Maury S, Esperou H, et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant 2005; 36: 649.
- Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004; 103: 78.
- Locasciulli A, Bacigalupo A, Alberti A, et al. Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation 1989; 48: 68.
- Salinger DH, McCune JS, Ren AG, et al. Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach. Clin Cancer Res 2006; 12: 4888.
- McDonald GB, McCune JS, Batchelder A, et al. Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. Clin Pharmacol Ther 2005; 78: 298.
- Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20: 18.
- Demirer T, Buckner CD, Appelbaum FR, et al. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996; 17: 491.
- Hassan M, Ehrsson H, Ljungman P. Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma 1996; 22: 395.
- Vaughan WP, Carey D, Perry S, et al. A limited sample strategy for pharmacokinetic therapy with intravenous busulfan. Biol Blood Marrow Transplant 2002; 8: 619.
- McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan. Does it improve clinical outcome? Clin Pharmacokinet 2000; 39: 155.
- Méresse V, Hartmann O, Vassal G, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992; 10: 135.
- Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977.
- Tay J, Tinmouth A, Fergusson D, et al. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 206.
- Azoulay D, Castaing D, Lemoine A, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant 2000; 25: 987.
- Rajvanshi P, McDonald GB. Expanding the use of transjugular intrahepatic portosystemic shunts for veno-occlusive disease. Liver Transpl 2001; 7: 154.
- Zenz T, Rössle M, Bertz H, et al. Severe veno-occlusive disease after allogeneic bone marrow or peripheral stem cell transplantation- role of transjugular intrahepatic portosystemic shunt (TIPS). Liver 2001; 21: 31.
- Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599.
- Ganem G, Saint-Marc Girardin MF, Kuentz M, et al. Venocclusive disease of the liver after allogeneic bone marrow transplantation in man. Int J Radiat Biol Phys 1988; 14: 879.
- McDonald GB, Sharma P, Matthews DE, et al. The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation 1985; 36: 603.
- Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005.
- Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002; 51: 275.
- Ibarrola C, Colina F. Clinicopathological features of nine cases of non-cirrhotic portal hypertension: current definitions and criteria are inadequate. Histopathology 2003; 42: 251.
- Nakanuma Y, Hoso M, Sasaki M, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology 1996; 28: 195.
- Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990; 11: 787.
- Shimamatsu K, Wanless IR. Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver. Hepatology 1997; 26: 343.
- Dill MT, Rothweiler S, Djonov V, et al. Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice. Gastroenterology 2012; 142: 967.
- Nakanuma Y, Ohta G, Sasaki K. Nodular regenerative hyperplasia of the liver associated with polyarteritis nodosa. Arch Pathol Lab Med 1984; 108: 133.
- Young ID, Segura J, Ford PM, et al. The pathogenesis of nodular regenerative hyperplasia of the liver associated with rheumatoid vasculitis. J Clin Gastroenterol 1992; 14: 127.
- Schouten JN, Nevens F, Hansen B, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther 2012; 35: 1424.
- Schouten JN, Garcia-Pagan JC, Valla DC, et al. Idiopathic noncirrhotic portal hypertension. Hepatology 2011; 54: 1071.
- Chang PE, Miquel R, Blanco JL, et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol 2009; 104: 1707.
- Seijo S, Reverter E, Miquel R, et al. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Dig Liver Dis 2012; 44: 855.
- Scoazec JY, Marche C, Girard PM, et al. Peliosis hepatis and sinusoidal dilation during infection by the human immunodeficiency virus (HIV). An ultrastructural study. Am J Pathol 1988; 131: 38.
- Goerdt S, Sorg C. Endothelial heterogeneity and the acquired immunodeficiency syndrome: a paradigm for the pathogenesis of vascular disorders. Clin Investig 1992; 70: 89.
- Leong SS, Cazen RA, Yu GS, et al. Abdominal visceral peliosis associated with bacillary angiomatosis. Ultrastructural evidence of endothelial destruction by bacilli. Arch Pathol Lab Med 1992; 116: 866.
- Kim SH, Lee JM, Kim WH, et al. Focal peliosis hepatis as a mimicker of hepatic tumors: radiological-pathological correlation. J Comput Assist Tomogr 2007; 31: 79.
- Iannaccone R, Federle MP, Brancatelli G, et al. Peliosis hepatis: spectrum of imaging findings. AJR Am J Roentgenol 2006; 187: W43.
- McDonald GB, Sharma P, Matthews DE, et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984; 4: 116.